Analysts Offer Predictions for Novartis FY2027 Earnings

Novartis AG (NYSE:NVS) – Stock analysts at Erste Group Bank lowered their FY2027 earnings per share estimates for shares of Novartis in a research note issued to investors on Thursday, April 2nd. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $9.73 for the year, down from their prior forecast of $9.80. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.04. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The firm had revenue of $13.86 billion for the quarter, compared to analyst estimates of $13.85 billion. During the same quarter last year, the company earned $1.98 EPS. The company’s revenue was up 1.4% on a year-over-year basis.

A number of other equities research analysts also recently weighed in on the company. HSBC reaffirmed a “reduce” rating and issued a $112.00 target price on shares of Novartis in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 12th. Wall Street Zen downgraded Novartis from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Barclays raised Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Finally, Weiss Ratings raised Novartis from a “buy (b)” rating to a “buy (a-)” rating in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Trading Up 2.1%

Shares of NVS stock opened at $154.36 on Thursday. The stock’s fifty day moving average price is $156.88 and its two-hundred day moving average price is $141.49. The company has a market cap of $326.07 billion, a PE ratio of 21.56, a P/E/G ratio of 2.64 and a beta of 0.52. Novartis has a fifty-two week low of $97.71 and a fifty-two week high of $170.46. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.89 and a current ratio of 1.12.

Institutional Investors Weigh In On Novartis

Several hedge funds have recently modified their holdings of NVS. Brighton Jones LLC boosted its holdings in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after acquiring an additional 2,666 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after acquiring an additional 11,444 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Novartis during the 1st quarter valued at $1,764,000. Sivia Capital Partners LLC boosted its holdings in shares of Novartis by 48.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares in the last quarter. Finally, Schnieders Capital Management LLC. acquired a new stake in shares of Novartis during the 2nd quarter valued at $202,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Dividend Announcement

The company also recently disclosed an annual dividend, which was paid on Monday, March 16th. Investors of record on Wednesday, March 11th were issued a dividend of $4.773 per share. The ex-dividend date of this dividend was Wednesday, March 11th. This represents a dividend yield of 306.0%. Novartis’s dividend payout ratio (DPR) is 43.02%.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.